JO3014B1 - مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة - Google Patents

مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة

Info

Publication number
JO3014B1
JO3014B1 JOP/2009/0075A JOP20090075A JO3014B1 JO 3014 B1 JO3014 B1 JO 3014B1 JO P20090075 A JOP20090075 A JO P20090075A JO 3014 B1 JO3014 B1 JO 3014B1
Authority
JO
Jordan
Prior art keywords
stearoyl
coa desaturase
heterocyclic inhibitors
derivatives
heterocyclic
Prior art date
Application number
JOP/2009/0075A
Other languages
English (en)
Inventor
Fonarev Julia
Fu 4-Jianmin
Hou 5-Duanjie
Zhang 10-Zaihui
Chowdhury Sultan
Sun Shaoyi
Kodumuru Vishnumurthy
Jia Qi
Pokrovskaia 8-Natalia
Dales Natalie
Original Assignee
Xenon Pharmaceuticals Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40740143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3014(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenon Pharmaceuticals Inc, Novartis Ag filed Critical Xenon Pharmaceuticals Inc
Application granted granted Critical
Publication of JO3014B1 publication Critical patent/JO3014B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات ذات الحلقات المختلفة التي تعدل نشاط ستياريل CO-A ديساتيوراز . طرق لاستعمال مثل المشتقات لتعديل نشاط ستياريل CO-A ديساتيوراز و تركيبات صيدلية تتضمن مثل هذه المشتقات التي تشتمل ايضا على ذلك
JOP/2009/0075A 2008-02-20 2009-02-19 مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة JO3014B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3013708P 2008-02-20 2008-02-20

Publications (1)

Publication Number Publication Date
JO3014B1 true JO3014B1 (ar) 2016-09-05

Family

ID=40740143

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0075A JO3014B1 (ar) 2008-02-20 2009-02-19 مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة

Country Status (28)

Country Link
US (2) US8049016B2 (ar)
EP (1) EP2245029B1 (ar)
JP (2) JP5507474B2 (ar)
KR (1) KR101584826B1 (ar)
CN (1) CN102007123B (ar)
AR (1) AR070429A1 (ar)
AU (1) AU2009216769A1 (ar)
BR (1) BRPI0907826A2 (ar)
CA (1) CA2715947C (ar)
CL (1) CL2009000381A1 (ar)
CO (1) CO6290655A2 (ar)
CR (1) CR11629A (ar)
CU (1) CU23890B1 (ar)
EA (1) EA022797B1 (ar)
EC (1) ECSP10010411A (ar)
HN (1) HN2010001647A (ar)
IL (1) IL207578A (ar)
JO (1) JO3014B1 (ar)
MA (1) MA32150B1 (ar)
MX (1) MX2010009158A (ar)
MY (1) MY156317A (ar)
NZ (1) NZ587350A (ar)
PE (1) PE20091473A1 (ar)
SV (1) SV2010003650A (ar)
TW (1) TWI457338B (ar)
UA (1) UA105000C2 (ar)
WO (1) WO2009103739A1 (ar)
ZA (1) ZA201005725B (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110341A1 (es) 2006-08-15 2011-06-21 Novartis Ag COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
MX2009006728A (es) * 2006-12-20 2009-09-09 Novartis Ag Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
PE20091473A1 (es) 2008-02-20 2009-10-23 Novartis Ag Heterociclos como inhibidores de esteaoril-coa desaturasa
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
SG178869A1 (en) * 2009-10-01 2012-04-27 Novartis Ag Pyrazole derivatives which modulate stearoyl-coa desaturase
AR091022A1 (es) * 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
CA2873672A1 (en) 2012-05-21 2013-11-28 Novartis Ag Novel ring-substituted n-pyridinyl amides as kinase inhibitors
CN109415371B (zh) * 2016-09-08 2021-07-09 四川科伦博泰生物医药股份有限公司 一种2-酰氨基噻唑衍生物及其制备方法与用途
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
CN114222732B (zh) * 2019-10-28 2023-04-04 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
EP4076448A4 (en) * 2019-12-20 2024-03-27 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058617A (en) 1972-10-04 1977-11-15 Ciba-Geigy Corporation Imidazoles and pharmaceutical composition
CH590267A5 (ar) * 1972-10-04 1977-07-29 Ciba Geigy Ag
IL44282A (en) 1974-02-25 1979-01-31 Ciba Geigy Ag 1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
ATE257703T1 (de) 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
CA2381215A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
US20050080113A1 (en) 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
WO2005077937A1 (en) 2004-01-09 2005-08-25 Cadila Healthcare Limited Substituted hydroxamic acid derivatives as tnf inhibitors
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
WO2006034341A2 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CA2580855A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US8541457B2 (en) * 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
RU2491285C2 (ru) 2006-06-05 2013-08-27 Новартис Аг Органические соединения
PE20110341A1 (es) * 2006-08-15 2011-06-21 Novartis Ag COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
AU2007288245A1 (en) 2006-08-24 2008-02-28 Novartis Ag 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders
JP5351025B2 (ja) * 2006-09-22 2013-11-27 ノバルティス アーゲー ヘテロ環式有機化合物
GB0621452D0 (en) * 2006-10-27 2006-12-06 Ucl Business Plc Therapy for liver disease
MX2009006728A (es) * 2006-12-20 2009-09-09 Novartis Ag Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
KR20100124262A (ko) * 2008-02-13 2010-11-26 에자이 알앤드디 매니지먼트 가부시키가이샤 비시클로아민 유도체
PE20091473A1 (es) 2008-02-20 2009-10-23 Novartis Ag Heterociclos como inhibidores de esteaoril-coa desaturasa
MX2010014572A (es) 2008-06-27 2011-03-24 Novartis Ag Compuestos organicos.

Also Published As

Publication number Publication date
JP5507474B2 (ja) 2014-05-28
ECSP10010411A (es) 2010-09-30
TWI457338B (zh) 2014-10-21
US8049016B2 (en) 2011-11-01
JP5813162B2 (ja) 2015-11-17
CA2715947C (en) 2016-10-25
CU23890B1 (es) 2013-04-19
WO2009103739A1 (en) 2009-08-27
BRPI0907826A2 (pt) 2019-12-10
AR070429A1 (es) 2010-04-07
MX2010009158A (es) 2010-09-24
CR11629A (es) 2010-11-16
ZA201005725B (en) 2011-04-28
CN102007123A (zh) 2011-04-06
CA2715947A1 (en) 2009-08-27
MA32150B1 (ar) 2011-03-01
US8318949B2 (en) 2012-11-27
UA105000C2 (uk) 2014-04-10
TW200942534A (en) 2009-10-16
JP2014132025A (ja) 2014-07-17
KR20100117677A (ko) 2010-11-03
SV2010003650A (es) 2011-07-05
JP2011512384A (ja) 2011-04-21
EP2245029A1 (en) 2010-11-03
AU2009216769A1 (en) 2009-08-27
MY156317A (en) 2016-02-15
CL2009000381A1 (es) 2010-09-10
HK1144808A1 (en) 2011-03-11
IL207578A (en) 2014-11-30
EP2245029B1 (en) 2015-04-15
EA201001315A1 (ru) 2011-06-30
HN2010001647A (es) 2013-11-11
CO6290655A2 (es) 2011-06-20
KR101584826B1 (ko) 2016-01-18
CN102007123B (zh) 2014-04-30
PE20091473A1 (es) 2009-10-23
IL207578A0 (en) 2010-12-30
CU20100170A7 (es) 2011-10-31
US20120014906A1 (en) 2012-01-19
NZ587350A (en) 2012-07-27
EA022797B1 (ru) 2016-03-31
US20090264444A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
JO3014B1 (ar) مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة
MX2009006728A (es) Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
MY153263A (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
WO2009156484A3 (en) Organic compounds
MX2009003080A (es) Compuestos organicos heterociclicos.
WO2007143597A3 (en) Organic compounds
TN2010000203A1 (en) Beta-lactamase inhibitors
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
TN2012000085A1 (en) Pyrazole derivatives which modulate stearoyl-coa desaturase
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
GEP20156241B (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
ZA201003352B (en) Heterocyclic derivatives as modulators of ion channels
MX2009010174A (es) Derivados de aza-adamantano ester y carbamato y metodos de uso de los mismos.
TN2010000378A1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
TN2010000598A1 (en) Organic compounds
WO2009120741A3 (en) Inhibition of trim62 activity reduces cancer cell proliferation